BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15239393)

  • 1. Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.
    Tefferi A; Pardanani A
    Int J Hematol; 2004 Jun; 79(5):441-7. PubMed ID: 15239393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
    Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
    Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis.
    Bain BJ
    Am J Hematol; 2004 Sep; 77(1):82-5. PubMed ID: 15307112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment.
    Tefferi A
    Mayo Clin Proc; 2005 Jan; 80(1):75-83. PubMed ID: 15667033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hematological disorders and hypereosinophilias].
    Malfuson JV; Fagot T; Konopacki J; Mangouka L; Souleau B; de Revel T
    Rev Med Interne; 2009 Apr; 30(4):322-30. PubMed ID: 19201511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modern diagnosis and treatment of primary eosinophilia.
    Tefferi A
    Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders.
    Pardanani A; Tefferi A
    Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
    Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
    Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
    Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A
    Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.
    Cheah CY; Burbury K; Apperley JF; Huguet F; Pitini V; Gardembas M; Ross DM; Forrest D; Genet P; Rousselot P; Patton N; Smith G; Dunbar CE; Ito S; Aguiar RC; Odenike O; Gimelfarb A; Cross NC; Seymour JF
    Blood; 2014 Jun; 123(23):3574-7. PubMed ID: 24687085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate in the treatment of hematologic malignancies.
    Piccaluga PP; Rondoni M; Paolini S; Rosti G; Martinelli G; Baccarani M
    Expert Opin Biol Ther; 2007 Oct; 7(10):1597-611. PubMed ID: 17916051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
    Pardanani A
    Acta Haematol; 2005; 114(1):41-51. PubMed ID: 15995324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eosinophilia: secondary, clonal and idiopathic.
    Tefferi A; Patnaik MM; Pardanani A
    Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
    Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
    Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
    [No Abstract]   [Full Text] [Related]  

  • 18. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
    Lahortiga I; Akin C; Cools J; Wilson TM; Mentens N; Arthur DC; Maric I; Noel P; Kocabas C; Marynen P; Lessin LS; Wlodarska I; Robyn J; Metcalfe DD
    Haematologica; 2008 Jan; 93(1):49-56. PubMed ID: 18166785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.